Outcome of Metastatic GIST in the Era before Tyrosine Kinase Inhibitors

[1]  H. Schlitt,et al.  Factors associated with disease progression in patients with gastrointestinal stromal tumors in the pre-imatinib era. , 2005, American journal of clinical pathology.

[2]  C. Bai,et al.  Prognostic value of KIT mutation in gastrointestinal stromal tumors. , 2005, World journal of gastroenterology.

[3]  C. Antonescu,et al.  Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation , 2005, Clinical Cancer Research.

[4]  M. Bertagnolli,et al.  Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT , 2005 .

[5]  J. Desai,et al.  Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST) , 2005 .

[6]  B. Iacopetta,et al.  Gastrointestinal stromal tumours (GISTs): a clinicopathological and molecular study of 66 cases , 2005, Pathology.

[7]  L. Sobin,et al.  Gastrointestinal Stromal Tumors of the Stomach: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 1765 Cases With Long-term Follow-up , 2005, The American journal of surgical pathology.

[8]  Rossella Bertulli,et al.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.

[9]  L. Sobin,et al.  A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential , 2004, Laboratory Investigation.

[10]  B. Matthews,et al.  Gastrointestinal stromal tumors of the stomach. , 2004, Minerva chirurgica.

[11]  N. Socci,et al.  Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic Site , 2004, Clinical Cancer Research.

[12]  Tae Won Kim,et al.  Prognostic Significance of c-kit Mutation in Localized Gastrointestinal Stromal Tumors , 2004, Clinical Cancer Research.

[13]  M. van Glabbeke,et al.  Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. , 2004, European journal of cancer.

[14]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  William Stafford Noble,et al.  Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. , 2003, The American journal of pathology.

[16]  B. Gunawan,et al.  Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours , 2003, The British journal of surgery.

[17]  Y. Nakanishi,et al.  Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients , 2003, Gastric Cancer.

[18]  J. Fletcher,et al.  Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Sigrid Stroobants,et al.  Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. , 2002, European journal of cancer.

[20]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[21]  Sigrid Stroobants,et al.  Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.

[22]  W. Jarnagin,et al.  Results of Hepatic Resection for Sarcoma Metastatic to Liver , 2001, Annals of surgery.

[23]  D. Tuveson,et al.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.

[24]  B. Yeap,et al.  The effect of surgery and grade on outcome of gastrointestinal stromal tumors. , 2001, Archives of surgery.

[25]  S. Hirota,et al.  Clinicopathological features of gastric stromal tumors. , 2000, Journal of experimental & clinical cancer research : CR.

[26]  S. Hirota,et al.  Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. , 1999, Cancer research.

[27]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[28]  G. Demetri,et al.  Clinical management of gastrointestinal stromal tumors: before and after STI-571. , 2002, Human pathology.

[29]  A. Davis,et al.  Malignant Gastrointestinal Stromal Tumors of the Small Intestine: A Review of 50 Cases From a Prospective Database , 2001, Annals of Surgical Oncology.

[30]  R. DeMatteo,et al.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. , 2000, Annals of surgery.

[31]  Jonathan J. Lewis,et al.  Salvage surgery for patients with recurrent gastrointestinal sarcoma , 2000, Cancer.